What is it about?
We used a markov model to portray the cost, health benefits and cost-effectiveness of providing MDMA-Assisted therapy to patients with chronic and severe PTSD. We reported results from the U.S. healthcare payer’s perspective for multiple analytic time horizons, (base-case is 30 years), and conducted extensive sensitivity analyses
Photo by Adam Flockemann on Unsplash
Why is it important?
This is the first economic analysis of a currently illegal psychedelic-based therapy to address a major mental health problem, namely PTSD. MDMA--assisted therapy provided to patients with severe or extreme chronic PTSD is cost-saving from a payer’s perspective while delivering substantial clinical benefit. This information is vital to program managers, policymakers and to both public and private insurers considering making this effective therapy available to all those who can benefit.
Read the Original
This page is a summary of: Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial, PLoS ONE, February 2022, PLOS, DOI: 10.1371/journal.pone.0263252.
You can read the full text:
The following have contributed to this page